ALLOVIR, INC.

Address: 139 MAIN ST STE 500 CAMBRIDGE, MA 02142-1530
County: MIDDLESEX
Country: UNITED STATES
UEI: CJ6ZNBK4CGQ9

Issue Date FY

Legal Entity Zip Code

Issue Date FY: 2024 ( Subtotal = $0 )

2024

2018

ALLOVIR, INC.

139 MAIN ST STE 500

CAMBRIDGE

02142-1530

MIDDLESEX

USA

R01FD005406

Phase I study of Viralym-A for the Treatment of Adenovirus disease - IND16258 (11/13/2014)

000

FDA

4/27/2024

Issue Date FY: 2022 ( Subtotal = $0 )

2022

2019

ALLOVIR, INC.

139 MAIN ST STE 500

CAMBRIDGE

02142-1530

MIDDLESEX

USA

R44HL132348

Path to Commercialization of the first ?off the shelf? T cell product

001

NIH

11/4/2021

2022

2019

ALLOVIR, INC.

139 MAIN ST STE 500

CAMBRIDGE

02142-1530

MIDDLESEX

USA

R44HL132348

Path to Commercialization of the first ?off the shelf? T cell product

000

NIH

10/28/2021

Issue Date FY: 2021 ( Subtotal = $0 )

2021

2018

ALLOVIR, INC.

2925 RICHMOND AVE STE 1274

HOUSTON

77098-3130

HARRIS

USA

R01FD005406

Phase I study of Viralym-A for the Treatment of Adenovirus disease - IND16258 (11/13/2014)

001

FDA

3/25/2021

2021

2018

ALLOVIR, INC.

139 MAIN ST STE 500

CAMBRIDGE

02142-1530

MIDDLESEX

USA

R01FD005406

Phase I study of Viralym-A for the Treatment of Adenovirus disease - IND16258 (11/13/2014)

000

FDA

3/24/2021

Issue Date FY: 2020 ( Subtotal = $0 )

2020

2019

ALLOVIR, INC.

2925 RICHMOND AVE STE 1274

HOUSTON

77098-3130

HARRIS

USA

R44HL132348

Path to Commercialization of the first ?off the shelf? T cell product

000

NIH

4/28/2020

Issue Date FY: 2019 ( Subtotal = $1,022,567 )

2019

VIRACYTE, INC.

2925 RICHMOND AVE STE 1274

HOUSTON

77098-3130

HARRIS

USA

R44HL132348

Path to Commercialization of the first ?off the shelf? T cell product

000

NIH

3/11/2019

$1,022,567

Issue Date FY: 2018 ( Subtotal = $1,053,343 )

2018

VIRACYTE, LLC

33 5TH AVE NW STE 800

NEW BRIGHTON

55112-3251

RAMSEY

USA

R44HL132348

Path to Commercialization of the first ?off the shelf? T cell product

000

NIH

4/1/2018

$986,769

2018

VIRACYTE, LLC

33 5TH AVE NW STE 800

NEW BRIGHTON

55112-3251

RAMSEY

USA

R01FD005406

Phase I study of Viralym-A for the Treatment of Adenovirus disease - IND16258 (11/13/2014)

000

FDA

2/20/2018

$249,697

2018

VIRACYTE, LLC

33 5TH AVE NW STE 800

NEW BRIGHTON

55112-3251

RAMSEY

USA

R44HL132348

Path to Commercialization of the first ?off the shelf? T cell product

001

NIH

7/19/2018

2018

VIRACYTE, LLC

33 5TH AVE NW STE 800

NEW BRIGHTON

55112-3251

RAMSEY

USA

R01FD005406

Phase I study of Viralym-A for the Treatment of Adenovirus disease - IND16258 (11/13/2014)

001

FDA

8/30/2018

-$183,123

Issue Date FY: 2017 ( Subtotal = $1,238,540 )

2017

VIRACYTE, LLC

33 5TH AVE NW STE 800

NEW BRIGHTON

55112-3251

RAMSEY

USA

R44HL132348

Path to Commercialization of the first ?off the shelf? T cell product

000

NIH

6/12/2017

$988,677

2017

2016

VIRACYTE, LLC

33 5TH AVE NW STE 800

NEW BRIGHTON

55112-3251

RAMSEY

USA

R01FD005406

Phase I study of Viralym-A for the Treatment of Adenovirus disease - IND16258 (11/13/2014)

002

FDA

8/10/2017

2017

2016

VIRACYTE, LLC

33 5TH AVE NW STE 800

NEW BRIGHTON

55112-3251

RAMSEY

USA

R01FD005406

Phase I study of Viralym-A for the Treatment of Adenovirus disease - IND16258 (11/13/2014)

001

FDA

1/27/2017

$249,863

All Categories

About

Search

Reports

Data Submission

Recipient Information

ALLOVIR, INC.

Address: 139 MAIN ST STE 500 CAMBRIDGE, MA 02142-1530

County: MIDDLESEX

Country: UNITED STATES

UEI: CJ6ZNBK4CGQ9

Issue Date FY Summary

Issue Date FY by OPDIV

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer